MedElevator
Войти в исследования Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
Phase II Trial of First-line Axitinib plus Nivolumab in Patients with Advanced Mucosal Melanoma.
СтатьяКлиническое исследование II фазыНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lochrin Sarah E, Kalvin Hannah L, Chen Monica F, Smithy James W, Momtaz Parisa, Postow Michael A, Station Shirlanna, Hochreiter Charlene, Panageas Katherine S, Yeh Randy, Barker Christopher A, Shoushtari Alexander N
Аннотация
PURPOSE: Mucosal melanoma is a rare subtype of melanoma with inferior response rates and outcomes to immunotherapy. Vascular endothelial growth factor (VEGF) signaling may contribute to immune resistance and represents a potential therapeutic target. We evaluated nivolumab plus axitinib in untreated, advanced mucosal melanoma in a Western population and explored escalation to triplet strategies for PD-1-refractory disease.
PATIENTS AND METHODS: In this single-center, investigator-initiated phase II study, patients with previously untreated unresectable or metastatic mucosal melanoma received nivolumab every 4 weeks and axitinib twice daily. The primary endpoint was objective response rate (ORR) per RECIST v1.1. A sequential phase Ib exploratory cohort evaluated treatment intensification with the addition of ipilimumab or stereotactic body radiotherapy (SBRT) at progression, with safety as the primary endpoint.
RESULTS: Among 20 evaluable patients, the ORR was 45% [95% confidence interval (CI), 23-68], including 4 complete responses (20%) and 5 partial responses (25%). The median duration of response was 21 months [95% CI, 8.6-Not Reached (NR)]. The median progression-free survival was 6.4 months (95% CI, 3.5-NR); the median overall survival was not reached. Grade 3 to 5 treatment-related adverse events occurred in 67%, including two treatment-related deaths. Seven patients received triplet therapy (ipilimumab, n = 5; SBRT, n = 2), with no unexpected toxicities observed.
CONCLUSIONS: Nivolumab plus axitinib demonstrated meaningful activity in advanced mucosal melanoma and warrants further evaluation in randomized studies. The addition of ipilimumab or SBRT after progression was feasible and may inform future studies, including biomarker-directed intensification to triplet strategies.
PATIENTS AND METHODS: In this single-center, investigator-initiated phase II study, patients with previously untreated unresectable or metastatic mucosal melanoma received nivolumab every 4 weeks and axitinib twice daily. The primary endpoint was objective response rate (ORR) per RECIST v1.1. A sequential phase Ib exploratory cohort evaluated treatment intensification with the addition of ipilimumab or stereotactic body radiotherapy (SBRT) at progression, with safety as the primary endpoint.
RESULTS: Among 20 evaluable patients, the ORR was 45% [95% confidence interval (CI), 23-68], including 4 complete responses (20%) and 5 partial responses (25%). The median duration of response was 21 months [95% CI, 8.6-Not Reached (NR)]. The median progression-free survival was 6.4 months (95% CI, 3.5-NR); the median overall survival was not reached. Grade 3 to 5 treatment-related adverse events occurred in 67%, including two treatment-related deaths. Seven patients received triplet therapy (ipilimumab, n = 5; SBRT, n = 2), with no unexpected toxicities observed.
CONCLUSIONS: Nivolumab plus axitinib demonstrated meaningful activity in advanced mucosal melanoma and warrants further evaluation in randomized studies. The addition of ipilimumab or SBRT after progression was feasible and may inform future studies, including biomarker-directed intensification to triplet strategies.